Cytek Biosciences Inc. (CTKB)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.58 |
Market Cap | 740.02M |
Revenue (ttm) | 197.84M |
Net Income (ttm) | -9.99M |
EPS (ttm) | -0.08 |
PE Ratio (ttm) | -71.81 |
Forward PE | 117.33 |
Analyst | Buy |
Ask | 5.88 |
Volume | 399,547 |
Avg. Volume (20D) | 753,735 |
Open | 5.66 |
Previous Close | 5.69 |
Day's Range | 5.65 - 5.82 |
52-Week Range | 4.66 - 9.33 |
Beta | 1.32 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full sp...
Analyst Forecast
According to 2 analyst ratings, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is $9.25, which is an increase of 61.01% from the latest price.
Next Earnings Release
Analysts project revenue of $60.89M, reflecting a 4.56% YoY growth and earnings per share of 0.11, making a 175.00% increase YoY.